Jazz Pharmaceuticals plc
Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing medicines for people with rare diseases, including patients with limited or no therapeutic options. Its marketed portfolio includes therapies for sleep disorders, epilepsy and cancer: Xywav and Xyrem for narcolepsy, Xywav for idiopathic hypersomnia, Epidiolex, marketed as Epidyolex in some markets, for seizures associated with certain epilepsies, and Ziihera, Modeyso, Zepzelca, Rylaze and Enrylaze for cancer treatment. Jazz makes money by commercializing its medicines in the U.S. and international markets, including products it develops and therapies it acquires or licenses from other companies. It also conducts research and development across clinical and preclinical programs, including work with third parties. Jazz Pharmaceuticals is headquartered in Dublin.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Morgan Stanley kept Jazz Pharmaceuticals at Overweight, raising its price target to $324 from $319, suggesting a 34.8% upside from the Nov 12 close of $240.37. Recent analyst price targets for the company range from $275 to $330.
Piper Sandler raised its price target for Jazz Pharmaceuticals to $330 from $310, maintaining an Overweight rating. This implies a 32.9% upside from the Nov 11 close of $248.24. Recent analyst targets for the company range from $275 to $319.
Jazz Pharmaceuticals director Bruce C. Cozadd sold 68,808 shares on November 6, 2026, for $16.24M at prices between $234.91 and $237.39 per share. The sales covered stock option exercise costs and taxes. Cozadd now owns 357,567 shares.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning JAZZ (Jazz Pharmaceuticals plc). Coverage has skewed bullish: 3 bullish, 0 neutral, and 2 bearish.
Recent JAZZ coverage spans financial news, insider activity and earnings.
In the last 30 days, JAZZ insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($18.1M). The most active reporter was COZADD BRUCE C with 5 filings. 25% of those filings were made under pre-arranged Rule 10b5-1 plans.
Street valuation bias turns more constructive via a higher PT, which can support near-term sentiment but is not a fundamental catalyst by itself.
Analyst target raise suggests potential upside for the stock.
The insider sale may signal reduced confidence, potentially pressuring the stock.
Significant insider sell may signal lack of confidence, prompting short-term price pressure.
Analyst downgrade suggests near-term downside pressure on Jazz stock.
AlphAI scores every news story that mentions JAZZ with an AI model for sentiment and relevance, and aggregates insider trades from Jazz Pharmaceuticals plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley kept Jazz Pharmaceuticals at Overweight, raising its price target to $324 from $319, suggesting a 34.8% upside from the Nov 12 close of $240.37. Recent analyst price targets for the company range from $275 to $330.
Piper Sandler raised its price target for Jazz Pharmaceuticals to $330 from $310, maintaining an Overweight rating. This implies a 32.9% upside from the Nov 11 close of $248.24. Recent analyst targets for the company range from $275 to $319.
Jazz Pharmaceuticals director Bruce C. Cozadd sold 68,808 shares on November 6, 2026, for $16.24M at prices between $234.91 and $237.39 per share. The sales covered stock option exercise costs and taxes. Cozadd now owns 357,567 shares.
COZADD BRUCE C sold 68,808 shares of Jazz Pharmaceuticals plc (JAZZ) at an average of $235.95 ($234.91–$237.39, $16.24M total) across 4 trades on 2026-11-06.
Bernstein lowered its price target for Jazz Pharmaceuticals (JAZZ) to $220 from $229, citing competition from Amgen's Imdelltra for Zepzelca in small cell lung cancer. Jazz's stock is up 79% in the past year. Jazz reported Q3 revenue of $1.24B, up 10% YoY, but a loss per share of $3.88 due to an IPR&D charge. Baird reiterated an Outperform rating with a $280 target.
Carr Patricia (SVP, Chief Accounting Officer) sold 1,413 shares of Jazz Pharmaceuticals plc (JAZZ) at an average of $231.36 ($231.27–$231.37, $0.33M total) across 2 trades on 2026-11-04.
COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $215.84 ($1.30M total) on 2026-11-02 under a Rule 10b5-1 trading plan.
Jazz Pharmaceuticals reported Q3 2026 revenues of $1.2B, up 10% YoY, and raised full-year guidance. The company expanded its epilepsy portfolio by acquiring Actio Biosciences and launched a new treatment for HER2+ gastroesophageal adenocarcinoma.
JP Morgan reaffirmed its Overweight rating for Jazz Pharmaceuticals and increased its price target to $310 from $300, suggesting a 44.6% upside from the Nov 2 close of $214.44. Recent analyst price targets for the company range from $275 to $319.
Morgan Stanley kept Jazz Pharmaceuticals at Overweight, raising its price target to $319 from $314, implying a 48.8% upside from the Nov 2 close of $214.44. Recent analyst targets range from $275 to $314.
